2023
Metformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeteransMetformin inhibits digestive proteases and impairs protein digestion in mice
Kelly C, Verdegaal A, Anderson B, Shaw W, Bencivenga-Barry N, Folta-Stogniew E, Goodman A. Metformin inhibits digestive proteases and impairs protein digestion in mice. Journal Of Biological Chemistry 2023, 299: 105363. PMID: 37863262, PMCID: PMC10663847, DOI: 10.1016/j.jbc.2023.105363.Peer-Reviewed Original ResearchConceptsGastrointestinal side effectsSide effectsDrug concentrationsDaily metformin doseFirst-line therapyType 2 diabetesEnteropeptidase activityPrescribed medicationsMetformin doseIntestinal lumenGastrointestinal tissuesMice exhibitMetforminProtein maldigestionHuman duodenumProtein digestionTrypsin activityDigestive enzymesMedicationsDiabetesMaldigestionDuodenumTherapyActivityMicePhosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities
Salovska B, Gao E, Müller‐Dott S, Li W, Cordon C, Wang S, Dugourd A, Rosenberger G, Saez‐Rodriguez J, Liu Y. Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities. Clinical And Translational Medicine 2023, 13: e1179. PMID: 36781298, PMCID: PMC9925373, DOI: 10.1002/ctm2.1179.Peer-Reviewed Original ResearchConceptsColorectal cancerLong-term metformin treatmentType 2 diabetesCRC cell linesColorectal cancer cellsBiguanide drug metforminPotential therapeutic opportunitiesMechanism of actionPharmacodynamic interactionsMetformin treatmentTreatment of cancerCRC cellsCell proliferation assaysClinical trialsBcl-2/Bcl-xL inhibitorMetforminDrug metforminTherapeutic opportunitiesProliferation assaysCancer cellsPotential cancer therapeuticsPotential roleExpression levelsCell linesCancer therapeutics
2022
Let-7 underlies metformin-induced inhibition of hepatic glucose production
Xie D, Chen F, Zhang Y, Shi B, Song J, Chaudhari K, Yang SH, Zhang GJ, Sun X, Taylor HS, Li D, Huang Y. Let-7 underlies metformin-induced inhibition of hepatic glucose production. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2122217119. PMID: 35344434, PMCID: PMC9169108, DOI: 10.1073/pnas.2122217119.Peer-Reviewed Original ResearchConceptsHepatic glucose productionAntidiabetic effectsMouse modelGlucose productionPotent antidiabetic actionsHepatocyte nuclear factor 4 alphaNuclear factor 4 alphaFunction mouse modelsHuman primary hepatocytesMetformin-induced inhibitionAntidiabetic actionTherapeutic effectGlucose homeostasisSuprapharmacological concentrationsRelevant dosesHepatic deliveryMetforminFetal isoformsPotential therapeuticsPrimary hepatocytesMost studiesLet-7Regulatory pathwaysHyperglycemiaDiabetesMetformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis
LaMoia TE, Butrico GM, Kalpage HA, Goedeke L, Hubbard BT, Vatner DF, Gaspar RC, Zhang XM, Cline GW, Nakahara K, Woo S, Shimada A, Hüttemann M, Shulman GI. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2122287119. PMID: 35238637, PMCID: PMC8916010, DOI: 10.1073/pnas.2122287119.Peer-Reviewed Original ResearchConceptsGlucose-lowering effectPlasma glucose concentrationComplex I activityHepatic gluconeogenesisType 2 diabetes mellitusGlucose concentrationGlycerol-3-phosphate dehydrogenase activityI activityDiabetes mellitusSelective inhibitionMetforminInhibitionRelevant concentrationsGluconeogenesisPhenforminVivoMost studiesDehydrogenase activityGalegineMellitusYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2021
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetforminCurrent Treatment of Pediatric Type 2 Diabetes
Samuels S, Van Name M, Guandalini C, Tamborlane W, Caprio S. Current Treatment of Pediatric Type 2 Diabetes. Contemporary Endocrinology 2021, 191-202. DOI: 10.1007/978-3-030-64133-7_18.Chapters
2020
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial
Brown JC, Zhang S, Ligibel JA, Irwin ML, Jones LW, Campbell N, Pollak MN, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer EP, Ng K, Abrams TA, Sanft T, Douglas PS, Hu FB, Fuchs CS, Meyerhardt JA. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research 2020, 13: 1055-1062. PMID: 32859615, PMCID: PMC7718298, DOI: 10.1158/1940-6207.capr-20-0188.Peer-Reviewed Original ResearchConceptsHs-CRPColorectal cancerPhysical activityHigh-sensitivity C-reactive proteinLow baseline physical activitySurvivors of breastTrial product estimandBaseline physical activityBiomarkers of inflammationC-reactive proteinMeasures of inflammationImproved clinical outcomesEffects of exerciseType 2 diabetesCombination of exerciseStandard therapyClinical outcomesCancer recurrenceObservational studyTreatment groupsInflammation outcomesMetforminIL6Factorial trialInflammationThe Authors Reply.
Clement Y, Singh S, Motilal S, Maharaj R, Nunez-Smith M. The Authors Reply. Ethnicity & Disease 2020, 30: 703-704. PMID: 32990691, PMCID: PMC7518543, DOI: 10.18865/ed.30.4.703.Peer-Reviewed Original ResearchCellular and Molecular Mechanisms of Metformin Action
LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocrine Reviews 2020, 42: 77-96. PMID: 32897388, PMCID: PMC7846086, DOI: 10.1210/endrev/bnaa023.Peer-Reviewed Original ResearchConceptsGlucose-lowering effectType 2 diabetesMetformin actionHepatic gluconeogenesisFirst-line therapyDosage of metforminRedox-dependent mechanismMechanism of actionMolecular mechanismsSafety profileMetformin inhibitsComplex I inhibitionMetformin concentrationsGlucose metabolismMetforminClinical settingPleotropic effectsDiscrepant effectsDiabetesAMPK activationCurrent literatureRelevant concentrationsI inhibitionRecent studiesRedox balanceEffects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis
Kaplan DE, Serper M, John BV, Tessiatore KM, Lerer R, Mehta R, Fox R, Aytaman A, Baytarian M, Hunt K, Albrecht J, Taddei TH, Group V. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. Clinical Gastroenterology And Hepatology 2020, 19: 2148-2160.e14. PMID: 32798709, DOI: 10.1016/j.cgh.2020.08.026.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisEnzyme inhibitors/angiotensinMetformin exposureHepatic decompensationHepatocellular carcinomaDiabetes mellitusPrognosis of cirrhosisPropensity-matched approachPre-existing diabetesRetrospective cohort studyLarge national cohortVeterans Health AdministrationMarginal structural modelsConcomitant statinCohort studyMultiple medicationsStatin exposureNational cohortCirrhosisPatientsDiabetesDecompensationMetforminConcomitant exposureHealth AdministrationA Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
Clement Y, Singh S, Motilal S, Maharaj R, Nunez-Smith M. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad. Ethnicity & Disease 2020, 30: 211-216. PMID: 32269463, PMCID: PMC7138437, DOI: 10.18865/ed.30.s1.211.Peer-Reviewed Original ResearchConceptsType 2 diabetesMetformin monotherapyPrimary health care facilitiesGenotype frequenciesHealth care facilitiesHealth Authority regionMedication initiationAdherent patientsClinical responseMost patientsDiabetic patientsGlycemic controlMaximal dosesStudy populationOrganic cation transportersBlood samplesCare facilitiesPatientsMetformin responseMonotherapyDiabetesMetforminFirst choiceGenetic polymorphismsSingle nucleotide polymorphismsOptimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight
Sivitz W, Phillips L, Wexler D, Fortmann S, Camp A, Tiktin M, Perez M, Craig J, Hollander P, Cherrington A, Aroda V, Tan M, Krakoff J, Rasouli N, Butera N, Younes N, Crandall J, Diane McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Stephanie Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, Ann White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Anne Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Mary L, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Ann Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Catherine Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Laura Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Irene Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Fan Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Brian Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Linder B, Bremer A, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care 2020, 43: 940-947. PMID: 32139384, PMCID: PMC7171946, DOI: 10.2337/dc19-1769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood GlucoseBody WeightCalibrationComparative Effectiveness ResearchDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinLiraglutideMaleMaximum Tolerated DoseMetforminMiddle AgedSitagliptin PhosphateSulfonylurea CompoundsWeight LossConceptsType 2 diabetesLow doseBody weightGlycemia Reduction ApproachesGlucose-lowering drugsSuboptimal glycemic controlExercise counselingMetformin therapyPrespecified analysisGlycemic controlPrimary outcomeMedication adherenceHigher HbASD changeDiabetesMetforminGlycemiaDoseWeight lossHbAGreater reductionDaysParticipantsGrade cohortsIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
Chapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.Chapters
2018
The present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent useIndividual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.
Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.Peer-Reviewed Original ResearchHigh-risk CaPCAP mortalityM1 diseaseHazard ratioTime-varying Cox proportional hazards modelsHigh-risk prostate cancerCox proportional hazards modelHigh-risk CaP.Post-diagnostic useProstate cancer mortalityUse of statinsPopulation-based studyEffect of statinsProstate cancer metastasisCause of deathProportional hazards modelMetformin useSEER databaseRandomized trialsCancer mortalityProstate cancerMedicare filesStatinsHazards modelMetformin
2017
H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses
Deng J, Mueller M, Geng T, Shen Y, Liu Y, Hou P, Ramillapalli R, Taylor HS, Paidas M, Huang Y. H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses. Cell Death & Disease 2017, 8: e3175-e3175. PMID: 29215608, PMCID: PMC5827203, DOI: 10.1038/cddis.2017.392.Peer-Reviewed Original ResearchMeSH KeywordsAdenosylhomocysteinaseAnimalsBase SequenceCell Line, TumorFemaleFetusGene Expression ProfilingGene Expression RegulationGluconeogenesisHepatocyte Nuclear Factor 4HepatocytesHumansHypoglycemic AgentsLiverMaleMaternal ExposureMetforminMethylationMicePregnancyPrenatal Exposure Delayed EffectsRNA, Long NoncodingSignal TransductionConceptsFetal liverPrenatal metformin exposureAnti-diabetic medicationsHuman liver cell lineHepatocyte nuclear factor 4αNuclear factor 4αMetabolic abnormalitiesMetformin exposureLiver cell lineH19 overexpressionMetabolic disordersAdult offspringFetal originAnimal studiesH19 expressionMouse fetusesMetforminElevated expressionLiverConcomitant activationCell linesFetusesGluconeogenic genesS-adenosylhomocysteine hydrolaseLiver developmentTelemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer
Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657386, DOI: 10.1200/cci.17.00044.Peer-Reviewed Original ResearchConceptsClinical trialsProstate cancerAdverse eventsSerum prostate-specific antigenStudy visitsClinical trials of metforminProstate-specific antigenTrial of metforminProspective clinical trialLocal therapySlow accrualOncology clinical trialsOral metforminStudy treatmentAnticancer activityTelehealth video visitsPatientsQuality of lifeSecondary objectivesPatient satisfactionCancerMetforminProstateTrial participantsTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply